<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109811</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02652</org_study_id>
    <secondary_id>GCC-0430</secondary_id>
    <secondary_id>CDR0000428259</secondary_id>
    <nct_id>NCT00109811</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer</brief_title>
  <official_title>A Phase 2 Study of Prostate Specific Antigen Peptide 3A (PSA: 154-163(155L) ) (NSC # 722932, IND#9787) With Montanide ISA-51(NSC #675756, IND #9787) or Montanide® ISA 51 VG (NSC 737063) Vaccination in Prostate Cancer Recurrent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well vaccine therapy works in treating patients with&#xD;
      recurrent prostate cancer. Vaccines made from peptides may help the body build an effective&#xD;
      immune response to kill tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the T-lymphocyte immune response in patients with recurrent adenocarcinoma of&#xD;
      the prostate treated with prostate-specific antigen (PSA) peptide vaccine (PSA-3A; PSA:&#xD;
      154-163 [155L]) emulsified in Montanide ISA-51.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the toxicity of this vaccine in these patients. II. Determine the effect of this&#xD;
      vaccine on serum PSA level in these patients.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Patients receive prostate-specific antigen (PSA) peptide vaccine (PSA-3A; PSA: 154-163&#xD;
      [155L]) emulsified in Montanide ISA-51 subcutaneously once in weeks 0, 2, 4, 6, 10, 14, and&#xD;
      18 in the absence of disease progression* or unacceptable toxicity.&#xD;
&#xD;
      NOTE: *A rise in PSA alone is not considered disease progression.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 1 and 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in frequency of CD8 T-lymphocyte precursors in peripheral blood mononuclear cells (PBMC), measured by ELISPOT assays</measure>
    <time_frame>From baseline to 1 week after the last dose of study treatment</time_frame>
    <description>A response is defined as at least a 5 fold higher frequency of INF-gamma secreting CD8 T cells after vaccination than before. A patient also will be considered a responder if no specific PSA: 154-163(155L) response was found before vaccination and a specific PSA: 154-163(155L) response is identified after vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of treatment on serum prostate-specific antigen level</measure>
    <time_frame>Up to 4 weeks after completion of study treatment</time_frame>
    <description>The PSA reduction is defined as is at least 50% fall in the serum PSA level after vaccination. The proportion of patients who showed a reduction in serum PSA will be estimated and corresponding 95% confidence intervals will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events graded according to NCI CTCAE version 3.0</measure>
    <time_frame>Up to 4 weeks after completion of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <condition>Recurrent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive PSA peptide vaccine (PSA-3A; PSA: 154-163 [155L]) emulsified in Montanide ISA-51 subcutaneously once in weeks 0, 2, 4, 6, 10, 14, and 18 in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PSA:154-163(155L) peptide vaccine</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>PSA PEP VAC</other_name>
    <other_name>PSA-3A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>IFA</other_name>
    <other_name>ISA-51</other_name>
    <other_name>Montanide ISA 51</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Must have undergone radical prostatectomy ≥ 3 months ago&#xD;
&#xD;
          -  Prostate-specific antigen (PSA) level ≥ 0.6 ng/mL and rising (after radical&#xD;
             prostatectomy) on ≥ 2 measurements separated by ≥ 3 months&#xD;
&#xD;
          -  HLA-A2-positive peripheral blood mononuclear cells by flow cytometry&#xD;
&#xD;
          -  No clinical evidence of local recurrence&#xD;
&#xD;
               -  No palpable induration or mass in prostatic fossa&#xD;
&#xD;
          -  No metastatic prostate cancer&#xD;
&#xD;
               -  No osseous metastases by bone scan&#xD;
&#xD;
          -  Performance status - ECOG 0-1&#xD;
&#xD;
          -  Performance status - Karnofsky 70-100%&#xD;
&#xD;
          -  More than 1 year&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Hepatitis B and C negative&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to study PSA peptide vaccine or Montanide ISA-51&#xD;
&#xD;
          -  No history of systemic autoimmune disease or autoimmune disease requiring&#xD;
             anti-inflammatory or immunosuppressive therapy&#xD;
&#xD;
               -  Patients with history of autoimmune thyroiditis are eligible provided the patient&#xD;
                  requires only thyroid hormone replacement therapy AND disease has been stable for&#xD;
                  ≥ 1 year&#xD;
&#xD;
          -  No known HIV positivity&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No primary or secondary immune deficiency&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No history of other uncontrolled illness&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No prior hormonal therapy&#xD;
&#xD;
          -  No concurrent systemic or ocular steroid therapy, except for any of the following:&#xD;
&#xD;
               -  Inhaled steroids for asthma&#xD;
&#xD;
               -  Limited topical steroids&#xD;
&#xD;
               -  Replacement doses of cortisone&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the prostate&#xD;
&#xD;
               -  Prior radiotherapy to the pelvis after radical prostatectomy allowed&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Richard Alexander</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland Greenebaum Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 3, 2005</study_first_submitted>
  <study_first_submitted_qc>May 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2005</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

